INSIGHT MOLECULAR DIAGNOSTIC (IMDX) Fundamental Analysis & Valuation

NASDAQ:IMDX • US68235C2061

Current stock price

4.26 USD
+0.34 (+8.67%)
At close:
4.26 USD
0 (0%)
After Hours:

This IMDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IMDX Profitability Analysis

1.1 Basic Checks

  • In the past year IMDX has reported negative net income.
  • IMDX had a negative operating cash flow in the past year.
  • IMDX had negative earnings in each of the past 5 years.
  • IMDX had a negative operating cash flow in each of the past 5 years.
IMDX Yearly Net Income VS EBIT VS OCF VS FCFIMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • The Return On Assets of IMDX (-138.33%) is worse than 83.17% of its industry peers.
Industry RankSector Rank
ROA -138.33%
ROE N/A
ROIC N/A
ROA(3y)-95.12%
ROA(5y)-75.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMDX Yearly ROA, ROE, ROICIMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

  • IMDX's Gross Margin of 54.73% is fine compared to the rest of the industry. IMDX outperforms 76.60% of its industry peers.
  • In the last couple of years the Gross Margin of IMDX has declined.
  • IMDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.21%
GM growth 5YN/A
IMDX Yearly Profit, Operating, Gross MarginsIMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. IMDX Health Analysis

2.1 Basic Checks

  • IMDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IMDX has been increased compared to 1 year ago.
  • Compared to 5 years ago, IMDX has more shares outstanding
  • IMDX has a worse debt/assets ratio than last year.
IMDX Yearly Shares OutstandingIMDX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
IMDX Yearly Total Debt VS Total AssetsIMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • IMDX has an Altman-Z score of -11.55. This is a bad value and indicates that IMDX is not financially healthy and even has some risk of bankruptcy.
  • IMDX has a worse Altman-Z score (-11.55) than 76.02% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.55
ROIC/WACCN/A
WACC9.02%
IMDX Yearly LT Debt VS Equity VS FCFIMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • A Current Ratio of 2.79 indicates that IMDX has no problem at all paying its short term obligations.
  • IMDX's Current ratio of 2.79 is on the low side compared to the rest of the industry. IMDX is outperformed by 66.92% of its industry peers.
  • A Quick Ratio of 2.73 indicates that IMDX has no problem at all paying its short term obligations.
  • IMDX has a worse Quick ratio (2.73) than 65.38% of its industry peers.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.73
IMDX Yearly Current Assets VS Current LiabilitesIMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. IMDX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 38.34% over the past year.
  • IMDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 520.87%.
  • The Revenue has been decreasing by -5.09% on average over the past years.
EPS 1Y (TTM)38.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.31%
Revenue 1Y (TTM)520.87%
Revenue growth 3Y-5.09%
Revenue growth 5YN/A
Sales Q2Q%126.09%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.56% on average over the next years. This is a very strong growth
  • IMDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 176.33% yearly.
EPS Next Y73.46%
EPS Next 2Y34.72%
EPS Next 3Y22.56%
EPS Next 5YN/A
Revenue Next Year545.1%
Revenue Next 2Y156.91%
Revenue Next 3Y176.33%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IMDX Yearly Revenue VS EstimatesIMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
IMDX Yearly EPS VS EstimatesIMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. IMDX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IMDX. In the last year negative earnings were reported.
  • Also next year IMDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMDX Price Earnings VS Forward Price EarningsIMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMDX Per share dataIMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IMDX's earnings are expected to grow with 22.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.72%
EPS Next 3Y22.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IMDX Dividend Analysis

5.1 Amount

  • No dividends for IMDX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMDX Fundamentals: All Metrics, Ratios and Statistics

INSIGHT MOLECULAR DIAGNOSTIC

NASDAQ:IMDX (3/20/2026, 8:01:31 PM)

After market: 4.26 0 (0%)

4.26

+0.34 (+8.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-26
Inst Owners52.29%
Inst Owner ChangeN/A
Ins Owners1.33%
Ins Owner Change142.28%
Market Cap141.22M
Revenue(TTM)4.40M
Net Income(TTM)-60.78M
Analysts78
Price Target8.5 (99.53%)
Short Float %0.73%
Short Ratio3.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-43.4%
Min EPS beat(2)-58.92%
Max EPS beat(2)-27.88%
EPS beat(4)0
Avg EPS beat(4)-109.34%
Min EPS beat(4)-342.79%
Max EPS beat(4)-7.78%
EPS beat(8)1
Avg EPS beat(8)-83.68%
EPS beat(12)4
Avg EPS beat(12)-68.66%
EPS beat(16)8
Avg EPS beat(16)-45.83%
Revenue beat(2)1
Avg Revenue beat(2)31.84%
Min Revenue beat(2)-10.25%
Max Revenue beat(2)73.92%
Revenue beat(4)3
Avg Revenue beat(4)743.56%
Min Revenue beat(4)-10.25%
Max Revenue beat(4)1553.71%
Revenue beat(8)3
Avg Revenue beat(8)351.14%
Revenue beat(12)5
Avg Revenue beat(12)231%
Revenue beat(16)5
Avg Revenue beat(16)146.85%
PT rev (1m)19.05%
PT rev (3m)19.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 32.08
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.83
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS0.13
BVpS-0.28
TBVpS-0.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -138.33%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.73%
FCFM N/A
ROA(3y)-95.12%
ROA(5y)-75.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.21%
GM growth 5YN/A
F-Score4
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.39%
Cap/Sales 43.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.73
Altman-Z -11.55
F-Score4
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)44.29%
Cap/Depr(5y)100.36%
Cap/Sales(3y)166.07%
Cap/Sales(5y)140.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.31%
EPS Next Y73.46%
EPS Next 2Y34.72%
EPS Next 3Y22.56%
EPS Next 5YN/A
Revenue 1Y (TTM)520.87%
Revenue growth 3Y-5.09%
Revenue growth 5YN/A
Sales Q2Q%126.09%
Revenue Next Year545.1%
Revenue Next 2Y156.91%
Revenue Next 3Y176.33%
Revenue Next 5YN/A
EBIT growth 1Y55.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year39.07%
EBIT Next 3Y9.21%
EBIT Next 5YN/A
FCF growth 1Y18.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.59%
OCF growth 3YN/A
OCF growth 5YN/A

INSIGHT MOLECULAR DIAGNOSTIC / IMDX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of INSIGHT MOLECULAR DIAGNOSTIC (IMDX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IMDX.


What is the valuation status for IMDX stock?

ChartMill assigns a valuation rating of 1 / 10 to INSIGHT MOLECULAR DIAGNOSTIC (IMDX). This can be considered as Overvalued.


How profitable is INSIGHT MOLECULAR DIAGNOSTIC (IMDX) stock?

INSIGHT MOLECULAR DIAGNOSTIC (IMDX) has a profitability rating of 1 / 10.